| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/29/2001 | US6238668 Administering polysaccharide |
| 05/29/2001 | US6238664 Process for stabilizing proteins |
| 05/29/2001 | US6238657 Three-dimensional silicone elastomers having polyether and higher alkyl functionality in their molecules form crosslinked networks; used as emulsifiers for oil-in-oil emulsion of silicone oils with organic oils |
| 05/29/2001 | US6238650 Said sunscreen active ingredient is in the form of sol-gel microcapsules containing at least one sunscreen compound. |
| 05/29/2001 | US6238647 Anticholinergic medicament which is selected from the group consisting of ipratropium, atropine, oxitropium and salts thereof |
| 05/29/2001 | US6238645 Methods of oxygenating tissues |
| 05/29/2001 | US6238284 Transdermal compositions with enhanced skin penetration properties |
| 05/29/2001 | CA2064915C Tumour necrosis factor binding ligands |
| 05/29/2001 | CA2049302C Aerosol carriers |
| 05/29/2001 | CA2033725C Pharmaceutical and cosmetic compositions containing a salt of cholanic acid |
| 05/29/2001 | CA2019273C Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
| 05/26/2001 | CA2291346A1 Antifungal solutions |
| 05/25/2001 | WO2001036656A2 A complex between hyaluronic acid and a biomolecule and its use |
| 05/25/2001 | WO2001036629A1 Transfer compounds, the production and the use thereof |
| 05/25/2001 | WO2001036612A1 Bifunctional molecules and their use in the disruption of protein-protein interactions |
| 05/25/2001 | WO2001036611A1 Process for the production of a reversibly inactive acidified plasmin composition |
| 05/25/2001 | WO2001036609A1 Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| 05/25/2001 | WO2001036608A1 Reversibly inactivated acidified plasmin |
| 05/25/2001 | WO2001036604A2 Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| 05/25/2001 | WO2001036599A1 Microparticle-based transfection and activation of dendritic cells |
| 05/25/2001 | WO2001036595A2 Methods for conditional transgene expression and trait removal in plants |
| 05/25/2001 | WO2001036583A1 Continuous-flow method for preparing microparticles |
| 05/25/2001 | WO2001036516A1 Biodegradable and thermosensitive polyphosphazenes and their preparation method |
| 05/25/2001 | WO2001036515A2 Polymeric compositions and a method of making the same |
| 05/25/2001 | WO2001036510A2 Use of poly(diallylamine) polymers |
| 05/25/2001 | WO2001036490A2 Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds |
| 05/25/2001 | WO2001036489A2 Erythropoietin forms with improved properties |
| 05/25/2001 | WO2001036487A2 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 05/25/2001 | WO2001036394A1 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer |
| 05/25/2001 | WO2001036290A1 Injection-moulded water-soluble container |
| 05/25/2001 | WO2001036007A2 Compositions of a combination of radioactive therapy and cell-cycle inhibitors |
| 05/25/2001 | WO2001036005A2 Targeted delivery of therapeutic and diagnostic moieties |
| 05/25/2001 | WO2001036004A2 Use of egf genistein for treatment egf-receptor expressing cancers |
| 05/25/2001 | WO2001036003A2 Selective cellular targeting: multifunctional delivery vehicles |
| 05/25/2001 | WO2001036002A1 Conjugates of hpma copolymer and ellipticin |
| 05/25/2001 | WO2001036001A2 Interferon gamma conjugates |
| 05/25/2001 | WO2001036000A1 Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
| 05/25/2001 | WO2001035999A1 Stable amorphous amifostine composition, and preparation thereof |
| 05/25/2001 | WO2001035998A1 Compositions for transdermal and transmucosal administration of therapeutic agents |
| 05/25/2001 | WO2001035987A1 An aqueous solution formulation of alpha-interferon |
| 05/25/2001 | WO2001035964A1 Substituted 1-benzazepines and derivatives thereof |
| 05/25/2001 | WO2001035943A2 Dextrose and insulin fluid formulation for intravenous infusion |
| 05/25/2001 | WO2001035942A2 Analgesic compositions containing buprenorphine |
| 05/25/2001 | WO2001035941A2 Novel composition based on a thiazolidinedione and metformin and use |
| 05/25/2001 | WO2001035940A2 Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride |
| 05/25/2001 | WO2001035937A2 Lipid complex of alkycyclines |
| 05/25/2001 | WO2001035934A1 Film preparation for biphasic release of pharmacologically active or other substances |
| 05/25/2001 | WO2001035933A2 A method of microencapsulation |
| 05/25/2001 | WO2001035929A2 Biodegradable polymer composition |
| 05/25/2001 | WO2001035927A2 Topical application of muscarinic analgesic drugs such as neostigmine |
| 05/25/2001 | WO2001035922A1 Novel positive latex and use in cosmetics |
| 05/25/2001 | WO2001035905A2 Personal care articles comprising cationic polymer coacervate compositions |
| 05/25/2001 | WO2001035764A1 Stable, spray-dried composition in a carbohydrate substrate and process for obtaining said composition |
| 05/25/2001 | WO2001035748A1 Bifunctional molecules having modulated pharmacokinetic properties and therapies based thereon |
| 05/25/2001 | WO2001035739A1 Use of polysiloxanes containing quaternary amino groups as formulation auxiliary agents, and agents containing the same |
| 05/25/2001 | WO2001012235A3 Targeted artificial gene delivery |
| 05/25/2001 | WO2001010446A3 Formulations for parenteral use of estramustine phosphate and albumin |
| 05/25/2001 | WO2001005362A3 Emulsifier-free finely dispersed water-in-oil-type systems |
| 05/25/2001 | WO2001000223A3 Multiple agent diabetes therapy |
| 05/25/2001 | WO2000067793A8 Death domain containing receptor 4 |
| 05/25/2001 | WO2000061191A3 Heat stable coated colloidal iron oxides |
| 05/25/2001 | WO2000042998A9 Multiparticulate bisoprolol formulation |
| 05/25/2001 | WO2000032555A8 Derivatives of (+)-venlafaxine and methods of preparing and using the same |
| 05/25/2001 | WO2000010582A8 Probiotic, lactic acid-producing bacteria and uses thereof |
| 05/25/2001 | CA2685349A1 Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
| 05/25/2001 | CA2396428A1 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 05/25/2001 | CA2391889A1 An aqueous solution formulation of alpha-interferon |
| 05/25/2001 | CA2391881A1 Transfer compounds, production and use thereof |
| 05/25/2001 | CA2391534A1 Selective cellular targeting: multifunctional delivery vehicles |
| 05/25/2001 | CA2391498A1 Substituted 1-benzazepines and derivatives thereof |
| 05/25/2001 | CA2391450A1 Targeted delivery of therapeutic and diagnostic moieties |
| 05/25/2001 | CA2391418A1 Stable amorphous amifostine composition, and preparation thereof |
| 05/25/2001 | CA2391396A1 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer |
| 05/25/2001 | CA2391080A1 Erythropoietin forms with improved properties |
| 05/25/2001 | CA2391032A1 Personal care articles comprising cationic polymer coacervate compositions |
| 05/25/2001 | CA2390864A1 Stable, spray-dried composition in a carbohydrate substrate and process for obtaining said composition |
| 05/25/2001 | CA2390292A1 Interferon gamma conjugates |
| 05/25/2001 | CA2389613A1 Continuous-flow method for preparing microparticles |
| 05/25/2001 | CA2389487A1 Process for the production of a reversibly inactive acidified plasmin composition |
| 05/25/2001 | CA2388846A1 Novel composition and use |
| 05/25/2001 | CA2388844A1 Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors |
| 05/25/2001 | CA2386873A1 Polymeric compositions and a method of making the same |
| 05/25/2001 | CA2359758A1 Methods for conditional transgene expression and trait removal in plants |
| 05/24/2001 | US20010001790 Topical formulations comprising skin penetration agents and the use thereof |
| 05/24/2001 | US20010001711 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 05/24/2001 | US20010001669 Compound delivery using rapidly dissolving collagen film |
| 05/24/2001 | US20010001668 Lozenge for the modified releasing of active substances in the gastrointestinal tract |
| 05/24/2001 | US20010001664 An agglomerate of microcrystalline cellulose and silicon dioxide of given particle size in intimate association |
| 05/23/2001 | EP1101497A1 STABILIZED PREPARATIONS OF $g(b)-LACTAM ANTIBIOTIC |
| 05/23/2001 | EP1101489A2 Sustained release heterodisperse hydrogel systems for insoluble drugs |
| 05/23/2001 | EP1100941A2 Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same |
| 05/23/2001 | EP1100820A1 Pectic substance as a growth factor stabilizer |
| 05/23/2001 | EP1100803A2 Pyrrolo 2,1-b] 1,3]benzothiazepines with atypical antipsychotic activity |
| 05/23/2001 | EP1100773A1 Saturated and unsaturated abietane derivatives, derived conjugates and uses in a diagnostic composition, a reagent and a device |
| 05/23/2001 | EP1100771A1 Compounds and compositions for delivering active agents |
| 05/23/2001 | EP1100549A2 A novel excipient for the lyophilization of aqueous suspensions of microparticles |
| 05/23/2001 | EP1100543A2 Conjugates targeted to the interleukin-2 receptors |
| 05/23/2001 | EP1100542A2 Peg-urate oxidase conjugates and use thereof |
| 05/23/2001 | EP1100541A1 Hydrogel for the therapeutic treatment of aneurysms |
| 05/23/2001 | EP1100535A1 Targeting pharmaceutical agents to injured tissues |